http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 16:25:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+May+28/26599286.html si-local-file:///var/storage/secattach/20260603/26599286.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+May+28/26599286.html Wed, 03 Jun 2026 16:25:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+May+28/26599286.html si-local-file:///var/storage/secattach/20260603/26599286.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cadrenal+Therapeutics%2C++++For%3A+May+28/26599286.html Wed, 03 Jun 2026 16:25:00 -0400 CVKD O.54961393 http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html <p>Cadrenal Therapeutics Inc. (NASDAQ: CVKD) will participate in the BIO International Convention 2026 Partnering Event from June 22-25 at the San Diego Convention Center. The company plans to showcase its drug development pipeline, including CAD-1005 and tecarfarin, according to a press release statement.</p> <p>CAD-1005 is described as a Phase 3-ready 12-lipoxygenase inhibitor under investigation for treating patients with Heparin-Induced Thrombocytopenia (HIT). The company completed an End-of-Phase 2 meeting with the FDA, which provided guidance for a single pivotal Phase 3 trial registration path. Phase 2 data showed CAD-1005 could reduce thrombotic events in patients with HIT.</p> <p>The drug has received FDA Orphan http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html Wed, 03 Jun 2026 09:02:10 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html <p>Cadrenal Therapeutics Inc. (NASDAQ: CVKD) will participate in the BIO International Convention 2026 Partnering Event from June 22-25 at the San Diego Convention Center. The company plans to showcase its drug development pipeline, including CAD-1005 and tecarfarin, according to a press release statement.</p> <p>CAD-1005 is described as a Phase 3-ready 12-lipoxygenase inhibitor under investigation for treating patients with Heparin-Induced Thrombocytopenia (HIT). The company completed an End-of-Phase 2 meeting with the FDA, which provided guidance for a single pivotal Phase 3 trial registration path. Phase 2 data showed CAD-1005 could reduce thrombotic events in patients with HIT.</p> <p>The drug has received FDA Orphan http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html Wed, 03 Jun 2026 09:02:10 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html <p>Cadrenal Therapeutics Inc. (NASDAQ: CVKD) will participate in the BIO International Convention 2026 Partnering Event from June 22-25 at the San Diego Convention Center. The company plans to showcase its drug development pipeline, including CAD-1005 and tecarfarin, according to a press release statement.</p> <p>CAD-1005 is described as a Phase 3-ready 12-lipoxygenase inhibitor under investigation for treating patients with Heparin-Induced Thrombocytopenia (HIT). The company completed an End-of-Phase 2 meeting with the FDA, which provided guidance for a single pivotal Phase 3 trial registration path. Phase 2 data showed CAD-1005 could reduce thrombotic events in patients with HIT.</p> <p>The drug has received FDA Orphan http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html Wed, 03 Jun 2026 09:02:10 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html <p>Cadrenal Therapeutics Inc. (NASDAQ: CVKD) will participate in the BIO International Convention 2026 Partnering Event from June 22-25 at the San Diego Convention Center. The company plans to showcase its drug development pipeline, including CAD-1005 and tecarfarin, according to a press release statement.</p> <p>CAD-1005 is described as a Phase 3-ready 12-lipoxygenase inhibitor under investigation for treating patients with Heparin-Induced Thrombocytopenia (HIT). The company completed an End-of-Phase 2 meeting with the FDA, which provided guidance for a single pivotal Phase 3 trial registration path. Phase 2 data showed CAD-1005 could reduce thrombotic events in patients with HIT.</p> <p>The drug has received FDA Orphan http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html Wed, 03 Jun 2026 09:02:10 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html <p>Cadrenal Therapeutics Inc. (NASDAQ: CVKD) will participate in the BIO International Convention 2026 Partnering Event from June 22-25 at the San Diego Convention Center. The company plans to showcase its drug development pipeline, including CAD-1005 and tecarfarin, according to a press release statement.</p> <p>CAD-1005 is described as a Phase 3-ready 12-lipoxygenase inhibitor under investigation for treating patients with Heparin-Induced Thrombocytopenia (HIT). The company completed an End-of-Phase 2 meeting with the FDA, which provided guidance for a single pivotal Phase 3 trial registration path. Phase 2 data showed CAD-1005 could reduce thrombotic events in patients with HIT.</p> <p>The drug has received FDA Orphan http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html Wed, 03 Jun 2026 09:02:10 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html <p>Cadrenal Therapeutics Inc. (NASDAQ: CVKD) will participate in the BIO International Convention 2026 Partnering Event from June 22-25 at the San Diego Convention Center. The company plans to showcase its drug development pipeline, including CAD-1005 and tecarfarin, according to a press release statement.</p> <p>CAD-1005 is described as a Phase 3-ready 12-lipoxygenase inhibitor under investigation for treating patients with Heparin-Induced Thrombocytopenia (HIT). The company completed an End-of-Phase 2 meeting with the FDA, which provided guidance for a single pivotal Phase 3 trial registration path. Phase 2 data showed CAD-1005 could reduce thrombotic events in patients with HIT.</p> <p>The drug has received FDA Orphan http://www.streetinsider.com/FDA/Cadrenal+Therapeutics+to+present+drug+candidates+at+BIO+2026+event/26596499.html Wed, 03 Jun 2026 09:02:10 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Press+Releases/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html <p align="center"><em>Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential</em></p> <p align="center"><em>12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is </em><em>a potential target for therapy and prevention of cancer</em></p> <p align="center"><em>Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular http://www.streetinsider.com/Globe+Newswire/Cadrenal+Therapeutics+to+Showcase+Phase+3-Ready+CAD-1005+and+Novel+12-LOX+Platform+at%C2%A0BIO+International+Convention+2026+Partnering+Event/26596409.html Wed, 03 Jun 2026 09:00:00 -0400 A.06822034 A.33934625 CVKD O.20026344 O.21005812 O.54961393 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cadrenal+Therapeutics%2C++++For%3A+May+29++Filed+by%3A+Pham+Quang+X/26594005.html si-local-file:///var/storage/secattach/20260602/26594005.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cadrenal+Therapeutics%2C++++For%3A+May+29++Filed+by%3A+Pham+Quang+X/26594005.html Tue, 02 Jun 2026 20:34:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cadrenal+Therapeutics%2C++++For%3A+May+29++Filed+by%3A+Pham+Quang+X/26594005.html si-local-file:///var/storage/secattach/20260602/26594005.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cadrenal+Therapeutics%2C++++For%3A+May+29++Filed+by%3A+Pham+Quang+X/26594005.html Tue, 02 Jun 2026 20:34:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cadrenal+Therapeutics%2C++++For%3A+May+11++Filed+by%3A+Pham+Quang+X/26575751.html si-local-file:///var/storage/secattach/20260529/26575751.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cadrenal+Therapeutics%2C++++For%3A+May+11++Filed+by%3A+Pham+Quang+X/26575751.html Fri, 29 May 2026 16:32:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cadrenal+Therapeutics%2C++++For%3A+May+11++Filed+by%3A+Pham+Quang+X/26575751.html si-local-file:///var/storage/secattach/20260529/26575751.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cadrenal+Therapeutics%2C++++For%3A+May+11++Filed+by%3A+Pham+Quang+X/26575751.html Fri, 29 May 2026 16:32:00 -0400 CVKD O.54961393 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cadrenal+Therapeutics%2C++++For%3A+May+22++Filed+by%3A+Pham+Quang+X/26552016.html si-local-file:///var/storage/secattach/20260526/26552016.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cadrenal+Therapeutics%2C++++For%3A+May+22++Filed+by%3A+Pham+Quang+X/26552016.html Tue, 26 May 2026 21:07:00 -0400 CVKD O.54961393